Thomas J. Walsh, MD, MBA, MS, presented “Testosterone Treatment and Prostate Cancer Risk” during the 43rd Annual Ralph E. Hopkins Urology Seminar on January 31, 2024, in Jackson Hole, Wyoming.
This content is available free to the GRU Community. Login or create an account to view it.
How to cite: Walsh, Thomas J. “Testosterone Treatment and Prostate Cancer Risk.” January 31, 2024. Accessed Nov 2024. https://grandroundsinurology.com/testosterone-treatment-and-prostate-cancer-risk/
Testosterone Treatment and Prostate Cancer Risk – Summary
Thomas J. Walsh, MD, MBA, MS, explores the relationship between testosterone treatment and risk for developing prostate cancer. Dr. Walsh begins by stating that he does not believe that testosterone treatment should be considered a risk factor for prostate cancer. He explains that according to the American Urological Association (AUA), testosterone therapy is appropriate treatment for patients with clinically significant testosterone deficiency after full discussion of potential adverse effects.
Dr. Walsh then outlines the positive and negative effects of testosterone therapy and shares data from a meta-analysis of the effect of testosterone replacement therapy on prostate cancer. He notes the issue of screening bias and compares the longitudinal comorbidities that showed virtually no difference in risk regardless of testosterone treatment.
Dr. Walsh concludes by sharing longitudinal data on cumulative testosterone treatment results that showed no increased risk of prostate cancer. Similarly, data did not show a statistical difference in prostate cancer risk according to the type of testosterone therapy a man received.
About The 43rd Annual Ralph E. Hopkins Urology Seminar:
The Ralph E. Hopkins Urology Seminar is a multi-day meeting focused on training urologists in the latest in assessing, diagnosing, and treating urologic conditions in the clinical setting. Updates are provided on urologic cancers, stone disease, urologic reconstruction, female urology, infertility, sexual function, emerging surgical techniques, and general urology. The 43rd iteration of the meeting took place from January 31st to February 2nd, 2024, in Jackson Hole, Wyoming.
For further educational activities from this conference, visit our collection page.
ABOUT THE AUTHOR
Dr. Thomas Walsh is a UW Professor and Vice Chair of Urology, Urology Section Head for UW Medical Center Northwest, and Director of the UW Men’s Health Center. His clinical interests include male reproductive and sexual medicine and surgery. He is the holder of the Endowed Professorship for Men’s Health, one of the only of its kind in the country.
Dr. Walsh completed his undergraduate training at the University of Oregon, where he graduated Phi Beta Kappa. He then received his medical degree from Northwestern University’s Feinberg School of Medicine, where he garnered the highest academic honors and was inducted into the Alpha Omega Alpha Honor Society. He completed his general and urologic surgical training at the University of Washington, during which time he served as a Ruth L. Kirschstein National Research Service Award Scholar and received a master’s degree in epidemiology at the UW School of Public Health. Dr. Walsh completed a fellowship in male infertility and erectile dysfunction at the University of California, San Francisco and directed the UCSF Center for Male Reproductive Health before returning to UW Medicine. During his time at UW, he founded the Men’s Health Center, has developed and maintained a robust and extramurally funded research program, and has trained several generations of residents and fellows.
Under Dr. Walsh’s leadership, the Men’s Health Center has become one of the busiest clinics of its kind in the country. He integrates the most advanced and minimally invasive diagnostic and treatment modalities into his practice. Dr. Walsh has been named as one of “Seattle’s Top Doctors” by both Seattle Magazine and Seattle Metropolitan Magazine, and is recognized as a leader among his peers.
